Teva Continues Divestitures To Close Allergan Deal With Sale To Impax
Executive Summary
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.
You may also be interested in...
Consolidation in Generics Sector As Impax Merges With Amneal
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
Consolidation in Generics Sector As Impax Merges With Amneal
The deal will create the fifth-largest generics company in the US with one of the largest pipelines, with about 150 pending ANDAs and 165 projects in active stages of development.
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.